Nuclea Biotechnologies

Health care company Nuclea Biotechnologies explores the genetic makeup of diseases as a means of determining ideal treatment. Using specialized technologies, Nuclea Biotechnologies' tests can anticipate a patient's reaction to certain therapies and the likelihood of a particular disease occurring again later in the patient's life.

Using recognized gene and protein profiles, Nuclea Biotechnologies has conducted detailed research into patient responses to treatments of irinotecan, a drug primarily used to treat colon cancer. These tests give a better idea of a treatment's potential effectiveness before proceeding with therapy.

Nuclea Biotechnologies takes a sample of a patient's tumor, which is then examined to obtain its gene and protein expression profiles. Next, the samples are tested by overexposing and underexposing them to irinotecan. This information can offer insight into the effectiveness of irinotecan to treat the patient's cancer. Nuclea Biotechnologies' gene and protein profile process may also be useful in determining responsiveness to other treatments.

Nuclea Biotechnologies methods also study antibodies that are paired with particular proteins within the gene and protein expression profiles. An IHC instrument marks the antibodies with labels that can later be detected. This test can be utilized in conjunction with tissue microarrays, which test hundreds of tumor samples simultaneously to get a better idea of how each of the samples will respond to irinotecan therapy. Nuclea Biotechnologies' process is considered less time-consuming and has the capability to offer a higher level of accuracy while being easier to use. Early tests from those who responded positively to irinotecan have bolstered the conclusion that the sensitivity and specific nature of the test is high.